Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Geron grants Janssen Biotech global rights to imetelstat; deal terminated

Executive Summary

Just a couple weeks after the FDA removed a clinical hold on its modified oligonucleotide imetelstat, cancer-focused Geron Corp. licensed Janssen Biotech Inc. exclusive worldwide rights to develop and commercialize the telomerase inhibitor (GRN163L) for oncology indications, including myeloid malignancies, and all other human therapeutic uses. Janssen will pay $35mm up front initially, up to $900mm in development, regulatory, and commercial milestones, plus sales royalties.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies